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Significant adverse events are associated with vaccination with the currently licensed smallpox vaccine. Candidate new-generation
smallpox vaccines such as the replication-defective modified vaccinia virus Ankara (MVA) produce very few adverse events in experimental
animals and in limited human clinical trials conducted near the end of the smallpox eradication campaign. Efficacy evaluation of such new-
generation vaccines will be extraordinarily complex, however, since the eradication of smallpox precludes a clinical efficacy trial and the
correlates of protection against smallpox are unknown. A combination of relevant animal efficacy studies along with thorough comparative
immunogenicity studies between traditional and new-generation smallpox vaccines will be necessary for vaccine licensure. In the present
study, a variety of immune responses elicited by MVA and the licensed smallpox vaccine Dryvax in a murine model were compared, with a
focus on mimicking conditions and strategies likely to be employed in human vaccine trials. Immunization of mice with MVA, using several
relevant vaccination routes including needle-free delivery, elicited humoral and cellular immune responses qualitatively similar to those
elicited by vaccination with Dryvax. Similar levels of vaccinia-specific IgG and neutralizing antibody were elicited by Dryvax and MVA
when higher doses (approximately 1 log) of MVAwere used for immunization. Antibody levels peaked at about 6 weeks post-immunization
and remained stable for at least 15 weeks. A booster immunization of either MVA or Dryvax following an initial priming immunization with
MVA resulted in an enhanced IgG titer and neutralizing antibody response. In addition, both Dryvax and various MVA vaccination protocols
elicited antibody responses to the extracellular enveloped form of the virus and afforded protection against a lethal intranasal challenge with
vaccinia virus WR.
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Introduction years that stocks of variola virus, the causative agent ofAlthough the world was declared free of smallpox by the
World Health Organization in 1980 following a remarkable
global public health effort of surveillance and vaccination
(Fenner et al., 1988), there has been speculation for several0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2005.06.002
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E-mail address: weirj@cber.fda.gov (J.P. Weir).smallpox, could illegally be obtained or already exist outside
of the officially sanctioned respositories for the virus
(Henderson, 1998). Since routine smallpox vaccination and
the production of vaccine ceased many years ago following
the WHO declaration, variola is considered by many as an
especially lethal and frightening potential bioterror agent
(Henderson, 1999). A major effort is underway to meet this
potential threat by developing diagnostic tools for early
disease recognition, pursuing antiviral drugs as therapeutic05) 164 – 175
C.A. Meseda et al. / Virology 339 (2005) 164–175 165options, and by the production and stockpiling of vaccines
against smallpox.
Traditional smallpox vaccines such as Dryvax, currently
the only licensed smallpox vaccine in the United States,
are live replication-competent strains of vaccinia virus.
Such vaccines were extremely effective against smallpox
during the campaign to eradicate the disease. However,
because of the known rate of complications that result from
vaccination with these vaccines, particularly in certain
high-risk populations (e.g., immunocompromised, the
elderly, or the very young), the development of new-
generation smallpox vaccines with a better safety profile
than historical vaccines is a high priority for public health
agencies. In fact, in the continued absence of smallpox, it
seems likely that the risks associated with smallpox
vaccination will need to be very low for widespread public
acceptance of a new vaccine.
Evaluation of candidate new-generation smallpox vac-
cines, however, will be extraordinarily complex.While safety
can be assessed in pre-clinical studies and then demonstrated
in controlled clinical trials, human efficacy trials are neither
feasible nor ethical. In addition, the correlates of protection
for smallpox are not known, making selection of a surrogate
endpoint(s) for efficacy (e.g., antibody response) difficult and
premature at the present time. One of the traditional endpoints
for efficacy evaluation of smallpox vaccines was the ‘‘take
rate’’ of the vaccine (the production of a typical Jennerian
vesicle and resulting vaccination scar). However, new-
generation vaccines (e.g., subunit vaccines, replication-
defective viruses, attenuated viruses), which are fundamen-
tally different from traditional vaccines, may not elicit a take,
or may elicit a take dissimilar to that of a traditional vaccine.
Thus, efficacy evaluation of new-generation smallpox
vaccines will likely depend on a combination of relevant
animal efficacy studies and comparative immunogenicity
studies between traditional smallpox vaccines and new-
generation vaccine candidates in both clinical trials and
animal models. Obviously, the number and types of animal
models used to evaluate efficacy, their relevance to the
pathophysiology of smallpox, the measurements used to
compare immunogenicity, and their relevance to the yet
undefined correlates of protection, are issues that must be
addressed for candidate smallpox vaccines. Fortunately, the
availability of limited stocks of the licensed vaccine Dryvax
should make some of these comparisons meaningful.
The aim of the present work was to compare the
immunogenicity and protective ability of a leading candidate
new-generation smallpox vaccine, modified vaccinia virus
Ankara (MVA), to the licensed smallpox vaccine Dryvax in a
mouse model of vaccination. MVA is a replication-defective
vaccinia virus derived from the Ankara strain by more than
500 passages through primary chicken embryo fibroblasts
(CEF) (Mayr et al., 1978). This virus grows to high titer in
CEF cells but replicates poorly, if at all, in human cells
(Blanchard et al., 1998; Carroll and Moss, 1997; Drexler et
al., 1998). MVA was administered to more than 120,000individuals in the latter stages of the smallpox eradication
campaign without significant adverse events (Mayr et al.,
1978; Stickl et al., 1974), although the thoroughness of
safety data monitoring at that time is unclear. Its actual
effectiveness against smallpox, however, has not been
determined since MVA vaccine was used in areas in which
smallpox was not endemic. We show here that immunization
of mice with MVA, using a variety of relevant vaccination
routes including needle-free delivery, elicits immune
responses similar to those elicited by vaccination with
Dryvax. Optimization of the elicited response and the
protective response, as measured in a pertinent type of
orthopoxvirus challenge, can be realized by exploring
various doses of MVA, combinations of vaccines, and
schedules of vaccination. In particular, we show that multiple
immunizations of MVA, as well as a combination of MVA
followed by Dryvax immunization, is effective in providing
protection against lethal challenge in the mouse model.Results
Dryvax immunization
In order to properly evaluate the immunogenicity and
protective capability of vaccination with modified vaccinia
virus Ankara in the mouse model, we first established a
comparator dose and route for Dryvax immunization which
would reproducibly elicit measurable immune responses
thought to be important for protective immunity. The results
from several experiments showed that the specific IgG
antibody response to vaccinia virus (Dryvax) was dose
dependent over a range of 105 to 107 pfu and was stable for
up to 15 weeks following immunization (data not shown).
Further, similar levels and duration of antibody response
were observed if an equivalent dose of Dryvax was
administered via scarification, intradermal (i.d.) injection,
or subcutaneous (s.c.) injection, as measured by vaccinia-
specific IgG and neutralizing antibody; there was a lower
antibody response when Dryvax was delivered by the
intramuscular (i.m.) route (data not shown). Therefore, in
experiments designed to assess the immunogenicity of
various MVA immunization protocols, we utilized a com-
parator dose of 106 pfu of Dryvax; by comparison, the
standard human dose of Dryvax is 2.5  105 pfu. In our
hands, intradermal delivery of Dryvax routinely resulted in a
consistent immune response as measured by antibody levels
and protection against challenge. This route of delivery was
used in all comparison experiments, although most experi-
ments included either a Dryvax scarification or subcuta-
neous delivery arm as well.
Immunogenicity of MVA
Although scarification is not a likely route of delivery
for vaccination with a non-replicating strain of vaccinia
Fig. 1. Time course of antibody response to Dryvax and MVA immuniza-
tion. Mice were immunized with Dryvax or MVA by different routes of
administration as indicated. Sera were taken at 3-week intervals for 15 weeks
and analyzed by ELISA for vaccinia-specific IgG using inactivated vaccinia
virus Dryvax. (A) 106 Dryvax and 106 MVA. (B) 107 MVA. (C) 108 MVA.
This experiment is representative of 2 experiments of the same design.
Table 1
Antibody response to Dryvax and MVA immunization
Group Vaccinia IgGa Neutralizing
antibodyb
A33R IgGc
PBS <1.0 <1.0 <1.0
Dryvax, 106, i.d. 3.61 T 0.28 1.36 T 0.30 3.41 T 0.42
MVA, 107, i.d. 4.21 T 0 1.86 T 0 3.26 T 0.64
MVA, 107, s.c. 3.81 T 0.42 1.68 T 0 2.05 T 0.21
MVA, 107, i.m. 4.01 T 0.42 1.53 T 0.21 2.96 T 0.21
MVA, 108, i.d. 4.46 T 0.21 2.13 T 0.04 3.86 T 0.21
MVA, 108, s.c. 4.46 T 0.07 1.96 T 0.15 3.11 T 0
MVA, 108, i.m. 4.46 T 0.07 1.79 T 0.01 3.41 T 0
a Vaccinia virus ELISA; 6 weeks post-vaccination; 2 independent
experiments. Mean IgG titer (log 10) T standard deviation. Limit of
detection 1:20.
b Neutralizing antibody assay; 3 weeks post-vaccination. Mean 50%
neutralization titer (log 10) T standard deviation; 2 independent experi-
ments. Limit of detection 1:10.
c A33R ELISA; 6 weeks post-vaccination. Mean IgG titer (log 10) T
standard deviation; 2 independent experiments. Limit of detection 1:10.
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ation. To compare the effectiveness of various routes of
MVA immunization, mice were immunized i.m., s.c., or i.d
at doses from 106 to 108 pfu, and sera were collected every
3 weeks for 15 weeks for evaluation of Dryvax specific
antibody by ELISA using inactivated virus. The specific
IgG antibody response to Dryvax was dose dependent overthis range, stable over the 15 weeks of observation, and
was not significantly affected by the route of adminis-
tration (Fig. 1). In the experiment shown here, doses of
107 and 108 MVA elicited IgG responses similar to or
greater than that of 106 Dryvax. Comparable results were
obtained from several experiments of similar design (e.g.,
Table 1 and data not shown), although the actual IgG
response to MVA was somewhat dependent upon the
individual preparation of virus used for inoculation, as
might be expected for a non-replicating virus (data not
shown).
As a measure of the broadness of the antibody response
to the various routes and doses of MVA used for
immunization, serum samples obtained at 6 weeks post-
vaccination from the experiment shown in Fig. 1 were
further evaluated by measurement of the vaccinia antibody
isotype (Fig. 2). Both Dryvax and MVA immunization
elicited high titers of IgG1, IgG2a, IgG2b, and IgG3,
indicating a robust response to vaccination with both
viruses and little effect of route of administration on the
response to MVA.
Further characterization and comparison between the
antibody response to Dryvax and MVA included measure-
ment of the neutralizing antibody response using a vaccinia
virus/h-galactosidase reporter gene assay (Manischewitz et
al., 2003). Sera from individual mice within a group were
pooled and tested for the ability to neutralize a h-
galactosidase expressing vaccinia virus WR (Table 1). The
neutralizing antibody titers elicited by MVA vaccination
were proportional to the dose used (107 or 108 pfu) and were
equal to or greater than that elicited by vaccination with 106
pfu of Dryvax.
Since an immune response to the extracellular enveloped
virion (EEV) form of vaccinia virus is believed to be
important for control of virus spread within the host, it was
of interest to determine whether the antibody response to
Dryvax and MVA vaccination included a response to this
Fig. 3. Cytokine production from splenocytes of immunized mice. Spleen
cells were taken at 6 weeks post-vaccination from mice immunized with
either 106 Dryvax, 107 MVA, 108 MVA, or mock-immunized (PBS) were
stimulated with inactivated Dryvax antigen and the supernatants were
assayed for the presence of IL-2 (A) or interferon g (B).
Fig. 2. Antibody isotype response to Dryvax and MVA immunization. Mice
were immunized with Dryvax or MVA at the indicated dose and route. Sera
were taken at 6 weeks post-immunization and analyzed by ELISA for
vaccinia-specific IgG (limit of detection 1:20) and IgG isotype (limit of
detection 1:40).
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components of the EEV, the A33R protein, was measured in
an antigen-specific ELISA (Table 1). Vaccination with 106
pfu of Dryvax and 107 or 108 pfu of MVA resulted in
substantial antibody responses to this component of the
EEV form of Dryvax.
The IgG1 and IgG2a response elicited when mice were
vaccinated with Dryvax or MVA suggested a response that
might include both Th-1 type humoral and Th-2 type
cellular immune responses. As a measure of the cellular
immune response elicited by Dryvax and MVA vaccina-
tion, we quantified the production of the cytokines released
from splenocytes from immunized mice that were re-
stimulated with vaccinia virus antigen in vitro. Individual
splenocyte cultures were prepared from each mouse of the
immunized groups at 6 weeks post-vaccination in two
independent experiments, stimulated in culture with
inactivated vaccinia antigen, and the supernatants were
assayed for the production of IL-2 and IFN-g (Th-1 type),
and IL-4 (Th-2 type) (Fig. 3). There was no detectable IL-
4 among the various groups (limit of detection 15 pg/ml;
data not shown). The quantity of IL-2 released from
splenocytes derived from mice immunized with either
Dryvax or MVA varied from mouse to mouse, but the
levels were significantly (P < 0.05) above background
(either unstimulated or mock-infected extract stimulated) or
above levels observed in control immunized animals (Fig.
3A). Similarly, the levels of IFN-g that were produced in
mice in groups immunized with Dryvax or MVA varied
from mouse to mouse, but were significantly above
background in a majority of the animals in each immu-
nized group (Fig. 3B). Again, these results suggest a
robust cellular response to vaccination with both Dryvax
and MVA.Enhanced immunogenicity to multiple immunizations with
MVA or MVA followed by Dryvax
Although traditional smallpox vaccines are administered
as a single immunization with a replicating vaccinia virus,
multiple immunizations of a non-replicating vaccine virus
may be employed if necessary to elicit a sufficient level of
protective immunity. To determine whether a second
immunization with MVA boosted the immune response
compared to a single immunization, mice were immunized
with 108 pfu of MVA and boosted with the same dose at
either 3 or 6 weeks. Sera were collected and evaluated for
specific vaccinia IgG at 3-week intervals over the following
12 weeks (Fig. 4). The IgG response was greater in animals
receiving a second MVA immunization compared to a single
immunization at each time point following the booster
immunization, and the response in animals receiving a
second immunization at 6 weeks was higher at 9 and 12
weeks than animals receiving a second MVA immunization
at 3 weeks. Further analysis of the effect of a booster
immunization of MVA on antibody response included
Fig. 4. Effect of an MVA booster immunization on vaccinia-specific
antibody response to MVA vaccination. Mice were immunized with 106
Dryvax or 108 MVA by the intradermal route of administration. Sera were
taken at 3-week intervals for 12 weeks and analyzed by ELISA for
vaccinia-specific IgG using inactivated vaccinia virus Dryvax. One group
of MVA-vaccinated mice was boosted with a second immunization of 108
MVA at 3 weeks; another group of MVA-vaccinated mice was boosted with
a second immunization of 108 MVA at 6 weeks. This experiment is
representative of 2 experiments of the same design.
Table 3
Antibody response to combinations of low-dose MVA and Dryvax
immunization at 12 weeks
Group Vaccinia IgGa Neutralizing
antibodyb
A33R IgGc
(A) PBS <1.0 <1.3 <1.0
(B) Dryvax, 106,
scar., day 0
3.68 T 0.30 1.83 T 0.12 2.81 T 0.43
(C) Dryvax, 106,
i.d., day 0
4.10 T 0.13 2.29 T 0.06 3.41 T 0.43
(D) No treatment
at day 0/Dryvax,
3.92 T 0.38 1.93 T 0.10 2.81 T 0.85
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and the IgG antibody response to the EEV protein A33R
(Table 2). Similar to the results for the measurement of total
vaccinia IgG response, the neutralizing antibody response,
measured at 9 weeks post-vaccination, was greatest in the
animals receiving 2 immunizations with MVA at a 6-week
interval. Similarly, the A33R IgG response at 12 weeks was
greatest in this group. For each measurement, the response
following 2 immunizations with 108 pfu of MVA at an
interval of 6 weeks was equal to or greater than the
corresponding antibody responses in animals immunized
with either 106 or 107 Dryvax. These results indicate that
multiple immunizations with MVA can result in an
enhanced immune response and suggest that the nature of
the vaccination strategy can have a significant effect on the
elicited response. In addition to a vaccination strategy thatTable 2
Antibody response to boosted MVA immunization
Group Vaccinia IgGa Neutralizing antibodyb A33R IgGc
PBS <1.0 <1.3 <1.0
Dryvax, 106 3.81 T 0 0.59 T 0.27 2.81 T 0
Dryvax, 107 4.51 T 0.42 2.16 T 0.20 3.26 T 0.21
MVA, 108 4.41 T 0.14 1.60 T 0.03 2.66 T 1.06
MVA, 108,
3-week boost
4.99 T 0.32 1.83 T 0.02 3.11 T 0.43
MVA, 108,
6-week boost
5.49 T 0.50 2.18 T 0.13 3.86 T 0.21
a Vaccinia virus ELISA; 12 weeks post-vaccination; 2 independent
experiments. Mean titer (log 10) T standard deviation. Limit of detection
1:20.
b Neutralizing antibody assay; 9 weeks post-vaccination. Mean 50%
neutralization titer (log 10) T standard deviation; 2 independent experi-
ments. Limit of detection 1:10.
c A33R ELISA; 12 weeks post-vaccination. Mean IgG titer (log 10) T
standard deviation; 2 independent experiments. Limit of detection 1:10.employs multiple immunizations of MVA, alternative small-
pox vaccination strategies may include an initial vaccination
with non-replicating virus vaccine followed by a second
immunization with a traditional replicating virus vaccine in
order to reduce the possibility of vaccine-associate adverse
events due to replicating vaccinia virus. To evaluate the
immunogenicity of such a strategy in the mouse model, we
compared the response to a single MVA immunization to a
two-dose MVA immunization schedule, similar to that
described above, and to a two-dose schedule of primary
MVA immunization followed by secondary Dryvax immu-
nization. When mice were immunized with 108 pfu of MVA
and boosted with 106 pfu of Dryvax, there was an increase
in vaccinia-specific IgG compared to a single immunization
with 108 pfu of MVA (5.02 and 4.63 mean log 10 titer,
respectively). In order to more accurately assess the effect of
the 2-dose immunization strategy and the effect of prior
MVA immunization on a Dryvax vaccination, we immu-
nized mice with a lower dose of MVA (106) and followed
this immunization with a 6-week booster immunization of
106 pfu of Dryvax or 106 pfu of MVA (Table 3). Total
vaccinia-specific IgG, A33R EEV IgG, and neutralizing
antibody were measured at 12 weeks. In these experiments,
the vaccinia-specific IgG response and the A33R EEV IgG
response to 106 pfu of MVAwas only slightly less than that
elicited by 106 pfu of Dryvax (Table 3, Groups C and E); the106, i.d., 6 weeks
(E) MVA, 106, i.d.,
day 0
3.89 T 0.34 1.37 T 0.50d 3.11 T 0
(F) No treatment at day
0/MVA, 106, i.d.,
6 weeks
3.60 T 0.26 1.15 T 0.21d 2.51 T 0.43
(G) MVA, 106, i.d.,
day 0/Dryvax, 106, i.d.,
6 weeks
4.94 T 0.04 2.21 T 0.23 3.71 T 0
(H) MVA, 106, i.d.,
day 0/MVA, 106, i.d.,
6 weeks
5.06 T 0.13 2.11 T 0.03 3.56 T 0.21
a Vaccinia virus ELISA; 12 weeks post-vaccination. Mean titer (log 10) T
standard deviation. Limit of detection 1:20.
b Neutralizing antibody assay; 12 weeks post-vaccination. Mean 50%
neutralization titer (log 10) T standard deviation; 2 independent experi-
ments. Limit of detection 1:20.
c A33R ELISA; 12 weeks post-vaccination. Mean IgG titer (log 10) T
standard deviation; 2 independent experiments. Limit of detection 1:10.
d In one of 2 experiments, no neutralizing antibody was detected; value of
1:10 (one dilution below limit of detection) used for calculation.
Fig. 5. Weight loss following intranasal vaccinia WR challenge. Groups of
5 mice were mock-immunized with PBS, or vaccinated by intradermal
injection with 106 Dryvax, 108 MVA, or a prime-boost combination of 108
MVA followed by either 106 Dryvax or 108 MVA. Animals in each group
were weighed daily for 15 days following challenge with 25 LD50s at 12
weeks post-vaccination (initial immunization). The mean percentage of the
initial body weight of each pool is shown. Animals which lost more than
25% of their body weight were sacrificed in accordance with the approved
animal protocol; plotted weights reflect only the surviving animals in each
group on each day. Day of animal deaths is noted — *.
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lower, however, and not detectable in some experiments.
When a low-dose MVA immunization was followed with a
booster immunization of either 106 pfu of MVA or 106 pfu
of Dryvax, there was a significant increase in the vaccinia-
specific IgG responses (P < 0.05) (Table 3, groups G and
H). The A33R-specific IgG and the neutralizing antibody
titers also increased after boosting and were equivalent to or
greater than a single Dryvax immunization (Table 3, Groups
G and H). Thus, these results confirm that a second
immunization with MVA can enhance the vaccinia virus-
specific immune response to vaccination. Furthermore, the
results suggest that prior immunization with MVA does not
interfere with the immune response to a subsequent Dryvax
immunization.
Protective effect of MVA and Dryvax immunization
To assess the protective capacity of MVA and Dryvax
immunization, we challenged vaccinated mice with a lethal
intranasal dose of vaccinia virus WR. Mice which were
mock-vaccinated with PBS succumbed to a challenge of
either 10 or 25 LD50s within 6–8 days (Table 4 and Fig. 5).
In contrast, all animals immunized intradermally with either
106 pfu of Dryvax, 108 pfu of MVA, or a prime-boost
combination of 108 pfu of MVA followed by either 106 pfu
of Dryvax or 108 pfu of MVA survived an intranasal
challenge with 25 LD50s of vaccinia virus WR (Table 4 and
data not shown). Furthermore, vaccination with a single
dose of 108 pfu of MVA resulted in a minimal weight loss
(<10%), as did a vaccination combination of 108 pfu of
MVA followed by 106 pfu of Dryvax (data not shown).
When mice that were immunized with a lower dose of 106
pfu of MVA were challenged with intranasal vaccinia virus
WR, 4 of 5 survived a challenge with 10 LD50s at either 6
weeks or 12 weeks post-vaccination (Table 4). When mice
received a single immunization of 106 pfu of MVA and were
challenged with 25 LD50s, 4 of 5 survived challenge at 6
weeks post-vaccination and 3 of 5 survived challenge at 12Table 4
Intranasal challenge with vaccinia virus WR following a single intradermal
immunization with 106 pfu Dryvax or MVA
Group Challenge Deaths/Totala MTDb
PBS 10 LD50–12 weeks 5/5 6.6 T 0.9
106 Dryvax 10 LD50–12 weeks 0/5 N/A
106 Dryvax 10 LD50–6 weeks 0/5 N/A
106 MVA 10 LD50–12 weeks 1/5 7
106 MVA 10 LD50–6 weeks 1/5 7
PBS 25 LD50–12 weeks 5/5 5.8 T 0.8
106 Dryvax 25 LD50–12 weeks 0/5 N/A
106 Dryvax 25 LD50–6 weeks 0/5 N/A
106 MVA 25 LD50–12 weeks 2/5 7 T 0
106 MVA 25 LD50–6 weeks 1/5 6
a Mice were sacrificed if their body weight decreased more than 25%
from the time of challenge.
b MTD — mean time to death T standard deviation.weeks post-vaccination (Table 4). In contrast, all animals
receiving 106 MVA and boosted 6 weeks later with either
106 pfu of MVA or 106 pfu of Dryvax survived (data not
shown).
All animals that were challenged by intranasal vaccinia
virus WR were also weighed daily to monitor the course of
disease. Calculation of the mean weight loss of animals in
each group following challenge revealed that the animals
that received two inoculations of MVA and/or Dryvax lost
less weight and recovered faster than animals receiving only
MVA or Dryvax (Fig. 5). Weight loss was most severe on
days 5 and 6 and the differences between single immuniza-
tions (Dryvax or MVA) and the combination vaccinations
(MVA/Dryvax and MVA/MVA) were greatest on those
days. The differences in weight loss among the different
groups were not significant, probably due to the limited
number of animals in any single experiment. However, a
similar pattern of weight loss (i.e., less weight loss in prime-
boost groups) was observed in all experiments.
Since some animals vaccinated with 106 pfu of MVA
survived i.n. challenge with vaccinia WR, whereas others
succumbed to challenge, we measured the vaccinia-specific
IgG in the pre-challenge sera of individual mice in an
attempt to correlate survival of animals with a specific
immune response to vaccination. We compared the pre-
challenge titers of individual animals in the 106 MVA group
that died following challenge to those that survived
challenge, and to the pre-challenge titers of individual
animals in the 106 Dryvax and 108 MVA groups (all of
whom survived challenge) (Fig. 6A). Of the mice who later
succumbed to challenge, there appeared to be a greater
range of values in the measured vaccinia-specific IgG titers,
including one IgG titer below the limit of detection.
Nevertheless, some individual titers within this group of
Fig. 6. Vaccinia-specific and A33R antibody response of individual mice
vaccinated with 106 Dryvax, 106 MVA, and 108 MVA. Sera were taken at
6 weeks post-vaccination and analyzed individually for the presence of
vaccinia-specific IgG (A) and A33R IgG (B) before subsequent challenge at
12 weeks. For the 106 Dryvax group, n = 8; for the 106 MVA (survivors),
n = 9; for the 106 MVA (deaths), n = 5; for the 108 MVA, n = 5.
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animals who survived challenge (Fig. 6A). Because we were
also interested in whether protection against challenge might
correlate with a pre-challenge antibody response to the
extracellular envelope form of the virus, we also measured
the specific antibody response to A33R as a representative
component of the EEV. There was a relatively narrow range
of measured A33R-specific IgG values in the individual
mice receiving either 106 pfu of Dryvax or 108 pfu of MVA
compared to the range of A33R IgG titers in animals
receiving 106 pfu of MVA. Nevertheless, the titer of A33R
antibody in the animals receiving 106 pfu of MVA did not
appear to correlate with survival, as there was undetectable
A33R antibody in some animals who survived and
relatively high A33R antibody in some animals who
succumbed to challenge (Fig. 6B). Finally, we measured
the neutralizing antibody titers in each of the individual sera,but the values from the mice receiving 106 pfu of MVAwere
too low to make a meaningful comparison (data not shown).
Although there are numerous other vaccinia virus-specific
immune responses that might be correlated with protective
immunity, the data from this set of experiments suggest the
difficulty of establishing an antibody correlate of protection
against lethality in this type of animal challenge study.Discussion
There are several formidable hurdles to the development
of new-generation vaccines for smallpox, the most signifi-
cant of which are related to the difficulty in evaluation of
efficacy in the absence of human clinical trials. Although
the pathway for efficacy evaluation is relatively straightfor-
ward, containing as one of its major components the use of
well-defined and -characterized animal models which reflect
key physiological elements of the disease in humans,
evaluation of efficacy in animal models is limited by our
incomplete understanding of the nature of protective
immunity to smallpox and to the related orthopoxviruses
used in such models. Arguments to support efficacy claims
for a new-generation smallpox vaccine using animal models
would be most persuasive if they were supported by data
from immunogenicity and protection studies that included a
direct comparison to a traditional smallpox vaccine for
which there is historical efficacy data in humans against
smallpox. The use of multiple animal models, determination
of the relative protective effect of vaccines against virus
challenge, and a complete characterization and comparison
of specific immune responses generated by vaccination,
both in animal models and in humans, are all important
components of such a comparative evaluation. There will
necessarily be some limitations inherent in each animal
model, in terms of our ability to extrapolate the results to the
vaccine situation in humans. Nevertheless, the use of
multiple animal models of protection and studies of
comparative immunogenicity between new-generation vac-
cines and licensed smallpox vaccines may provide a strong
case for the efficacy of a new-generation smallpox vaccine
(Rosenthal et al., 2001). Even without knowing the relative
importance of individual immune responses for protection
following vaccination, the more similar the responses
evoked by a new-generation vaccine are to those evoked
by a traditional licensed vaccine, the greater our confidence
will be for its effectiveness.
In the studies reported here, we have measured a battery
of immune responses in the mouse to the licensed smallpox
vaccine, Dryvax, and to MVA, a leading new-generation
vaccine candidate. Although mouse models of immunoge-
nicity and protection will certainly not be the only relevant
animal models used in the evaluation of new-generation
smallpox vaccines, they will undoubtedly be important
ones. From a practical point of view, mouse models can
provide statistical power for comparative evaluation. In
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for the mouse, including vaccinia WR, ectromelia, and
cowpox (Bray et al., 2000; Martinez et al., 2000; Schriewer
et al., 2004; Turner, 1967; Williamson et al., 1990), and
there are multiple routes of virus challenge that can be
employed, including intranasal, aerosol, and systemic (e.g.,
intraperitoneal and intravenous). To facilitate evaluation of
candidate vaccines in the mouse model, we have compared
a variety of immune responses to Dryvax and MVA
vaccination, focusing on a variety of conditions and
strategies that are likely to be employed in human vaccine
trials.
A comparator dose of 106 pfu of Dryvax was used in the
reported immunogenicity and protection experiments. This
is similar to an average human dose (2.5  105 pfu, as
defined by titration on the chorioallantoic membranes of
chick embryos and delivered between the two prongs of a
bifurcated needle) (Henderson and Moss, 1999). We
compared delivery of Dryvax using various routes of
administration, including scarification at the base of the tail
(although not with a bifurcated needle) and found little
difference in the response to the virus when delivered by
scarification, subcutaneous, or intradermal routes. We
routinely delivered Dryvax by intradermal injection with a
Biojector 2000 device because of the reliability and
accuracy in controlling the dose of virus delivered to the
animal (Conry et al., 1999) (Meseda, Stout, and Weir;
manuscript submitted). While the exact dose of Dryvax
being delivered is not a major issue in a human trial where
‘‘take’’ can be monitored, it is of some concern in a mouse
immunogenicity study where the effect of different doses is
being compared. Indeed, in our experiments, there was a
clear effect of Dryvax dose on immune response (e.g., Table
2), underscoring the need for accurate measurement of the
delivered dose of Dryvax in a comparative study. Further,
scarification is not likely to be used in clinical trials of non-
replicating viruses such as MVA that do not produce a
‘‘take’’ and was not evaluated here as a means of MVA
administration. We felt it important to compare the relative
immune responses produced by MVA and Dryvax using at
least one common route of administration. The results from
our studies indicated that there was little difference in the
immune response as a result of delivery route used to
administer MVA. Although i.m. administration has not been
an effective route of delivery for traditional replicating
smallpox vaccines, this route was effective for MVA. Since
each of the routes of delivery utilized in our experiments is a
possible route of administration for MVA in human trials, it
is reassuring that all routes of delivery are effective in the
mouse model. The effectiveness of a needle-free delivery
system for delivery of replicating and non-replicating
vaccines suggests that this mode of vaccine administration
would also be feasible for use in clinical trials. Since there
are advantages to needle-free delivery (e.g., elimination of
needle disposal, prevention of needlestick injury, patient
preference, etc.) (McKenzie, 1982), this platform forvaccine delivery may provide additional options for
vaccination programs.
In order to better understand the duration of the immune
response to vaccination and because some strategies of
vaccination will likely involve multiple immunizations with
new-generation smallpox vaccines over an extended time-
period, we analyzed the antibody response to vaccination in
mice over a relatively long period of time (12–15 weeks)
following the initial dose of vaccine. By each measurement,
the elicited immune response was stable over this time
frame for both Dryvax and MVA. Further, when animals
received a second dose of MVA, the antibody response was
elevated compared to a single immunization, and was stable
for the remainder of the observation period (6 to 9 weeks).
These results suggest that non-replicating vaccinia virus
vaccines may be able to induce a durable immune response
comparable to that obtained by vaccination with a tradi-
tional replication-competent vaccine. In the challenge
experiments reported here, similar levels of protection were
found regardless of whether animals were challenged at 6
weeks or 12 weeks after vaccination with either 106 pfu of
Dryvax or MVA. In other recently reported studies, mice
immunized with 106 pfu or 107 pfu of MVA survived an
intranasal challenge with 106 vaccinia WR at 4 weeks post-
vaccination (Wyatt et al., 2004; Belyakov et al., 2003).
While all such protection studies are encouraging in regard
to the duration of protective immunity, the results should be
viewed with some caution. To date, comprehensive studies
which assess the level of protective immunity versus
challenge dose and versus time after vaccination have not
been reported.
The murine immune responses that were measured in this
study included anti-vaccinia virus IgG using inactivated
Dryvax virus as antigen, A33R-specific IgG, vaccinia virus
neutralizing antibody using a vaccinia virus WR reporter
gene assay (Manischewitz et al., 2003), and production of
cytokines from vaccinia antigen stimulated spleen cells. The
Dryvax antigen used in the vaccinia virus ELISA was
prepared from infected cells, and thus consists of predom-
inately IMV and measures the antibody response to this
form of the virus. A measure of the EEV antibody response
was obtained by using a Dryvax-derived EEV-specific
antigen, A33R. In general, relatively similar antibody
responses were measured by each of these assays following
vaccination with either Dryvax or MVA or combinations of
the two vaccines. Other recent studies in mouse models
have reported a similar correlation of Dryvax and MVA
IMV and A33R EEV murine antibody using vaccinia virus
WR, rather than Dryvax, as a source of antigen for ELISAs
(Wyatt et al., 2004). In our studies, we focused on A33R as
a representative antigen of the EEV because A33R has been
shown to be partially protective in animal models when used
as either a protein subunit vaccine or delivered as a DNA
vaccine (Fogg et al., 2004; Hooper et al., 2000). Recently,
studies reported that the EEV of vaccinia virus is lysed by
complement in the presence of antibodies to A33R (Lustig
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generation of protective immunity. In particular, neutralizing
antibody against the EEV is thought to be directed primarily
against the B5R protein (Bell et al., 2004; Galmiche et al.,
1999). Understanding the immune response to other EEV
proteins will be important for a complete comparison of the
protective immunity elicited by Dryvax and MVA in a
mouse model. These studies are currently underway.
The neutralizing antibody responses to vaccination also
followed a similar pattern to the IgG responses. Since a
lacZ-expressing purified vaccinia virus was utilized in this
assay, the neutralizing antibody that was measured was
primarily directed to the IMV form of the virus. Although
we have also measured the presence of EEV neutralizing
antibody following immunization using a comet inhibition
assay (manuscript in preparation), assays which are capable
of quantifying the levels of EEV neutralizing antibody have
not been reported. Vaccination with both MVA and Dryvax
resulted in the production of IL-2 and IFN-g from spleen
cells stimulated with inactivated Dryvax. Although there
was a relatively wide range of values measured among the
individual mice, there was little overall difference in the
production of both cytokines between the MVA- and
Dryvax-immunized animals and between the animals immu-
nized with either 107 or 108 pfu of MVA (Fig. 3). As shown
previously, inactivated vaccinia virus only activates CD4+ T
cells (Tscharke and Smith, 1999). However, in other
recently reported studies in which the CD8+ T cell response
was compared in MVA- and Dryvax-immunized animals,
there were also relatively minor differences in the responses
measured at times greater than 4 weeks. In one study, a
dose-dependent T cell response (measured by IFN-g
producing spleen cells in an ELISPOT assay) was reported
when lower doses of MVA (102–106 pfu) were used for
immunization (Belyakov et al., 2003). In that study and a
separate study (Wyatt et al., 2004), a somewhat higher
percentage of IFN-g producing CD8+ spleen cells were
found in Dryvax immunized animals at 4 weeks post-
immunization, although there was little difference by 5
weeks post-vaccination (Wyatt et al., 2004). Taken together,
however, the results of several types of analyses make it
clear that Dryvax and MVA elicit a robust T cell response
following vaccination.
It is not yet clear which combination of assays is the most
relevant for comparison of immune response between
candidate vaccines. It seems likely that an EEV antibody
response in addition to an IMV response will be important
for protective immunity, based on the ineffectiveness of
inactivated smallpox vaccines (Boulter et al., 1971; Turner
and Squires, 1971) (which presumably would elicit a poor
EEV response in the absence of replication) and the
protective effect of recently reported DNA vaccines in some
animal models (Hooper et al., 2000, 2003, 2004). The
contribution, however, of individual EEV antigens to the
generation of protective immunity is unresolved. Similarly,
the role of the cellular immune response in the generation ofthe protective immunity engendered by vaccination, and the
contribution of specific T cell antigens in this response is
unclear. Although passive transfer of antibody from Dryvax-
immunized mice can be protective (Belyakov et al., 2003),
both B cell-deficient and CD8+ T cell-deficient mice can be
successfully vaccinated with MVA and survive a lethal
vaccinia WR challenge (Wyatt et al., 2004), and immuniza-
tion with a single CD8+ T cell peptide epitope from vaccinia
virus can provide protection against disease induced by
intranasal vaccinia WR challenge (Snyder et al., 2004). As
noted above, however, the relative levels of protection
afforded by various vaccination procedures compared to
licensed smallpox vaccine have not been reported for animal
challenge models. Indeed, our initial analysis of antibody
response as a predictor of survival following intranasal
vaccinia WR challenge emphasized the difficulty of
establishing an immunological correlate of protection in
animal models. More extensive studies to define the roles of
the cellular and humoral immune response and the relative
contribution of individual antigens in the protective
response to vaccination are warranted. Such an under-
standing would guide the selection of the relevant assays
used to compare new-generation vaccines with traditional
smallpox vaccines.
Considering the difficulties in efficacy evaluation for
new-generation smallpox vaccines, and the fact that
candidate vaccines such as MVA are fundamentally differ-
ent than traditional replication-competent virus vaccines
such as Dryvax, it is likely that various schemes of
vaccination will be explored to maximize the effectiveness
and utility of these candidate vaccines. As shown here, the
addition of a second dose of MVA, and the timing of that
dose, has an effect on the resulting immune response.
Similar empirical studies in clinical trials could be used to
determine the most effective vaccination regimen for a
combination MVA vaccine in humans. In addition, a booster
immunization with Dryvax also effectively boosted the
response to an initial MVA immunization. This effect was
more dramatic when a relatively low dose of MVAwas used
for the initial immunization. Such a scheme of vaccination
(i.e., MVA followed by traditional smallpox vaccination)
may be considered as a means of reducing the rate of
adverse events associated with traditional smallpox vacci-
nation, provided that vaccine efficacy is not compromised
by such a pre-immunization. Importantly, this did not seem
to be the case in the mouse model based on the immune
responses that we measured and the protection afforded by
intranasal challenge with vaccinia WR. As reported recently,
non-human primates immunized with MVA followed by
Dryvax responded with higher antibody titers and were just
as well protected against an i.v. challenge of monkeypox as
animals that only received a Dryvax immunization (Earl et
al., 2004). Thus, the initial indications from both mouse and
non-human primate models, suggest promise for an MVA/
Dryvax vaccination procedure. Obviously, further evalua-
tion of such vaccination schemes will include investigations
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(as they are identified) and the rigor of the challenge doses
used in each animal model.
In summary, the results presented here indicate that
combinations of MVA are as effective as Dryvax in eliciting
immune responses and inducing protective immunity in a
mouse model and suggest the effectiveness of MVA as a
new-generation smallpox vaccine in this supportive animal
model. These findings confirm and support similar findings
in other studies and extend such findings by further
exploring the effects of routes of vaccination, the duration
of the murine immune response, and the effectiveness of
combinations of MVA and Dryvax vaccination schemes.
Key remaining issues for the comparative evaluation of the
effectiveness of MVA in a supportive mouse model of
orthopoxvirus infection include the relevance of the specific
immune responses being measured, whether these responses
indeed reflect true correlates of protection against smallpox,
the relevance of the orthopoxvirus used for challenge and
the route in which it is delivered, and whether the relative
strength of protection between a candidate vaccine and
licensed smallpox vaccine can be measured. These issues
are under investigation.Materials and methods
Cells and viruses
Stocks of vaccinia virus WR and Dryvax were grown and
titered in BS-C-1 cells. Modified vaccinia virus Ankara
(MVA) was grown and titered on chicken embryo fibro-
blasts (CEF). The preparation of virus stocks, purification
on sucrose cushions, and titration by plaque assay were
performed as previously described (Earl et al., 1998).
Mice and immunization
Male BALB/cByJ mice were obtained from the Jackson
Laboratory, Bar Arbor, ME. They were housed in cages at a
core facility in CBER, where sterile feed and drinking water
were provided. Mice were routinely cared for by the
Division of Veterinary Services. Care and handling of
animals were performed according to guidelines provided
by the Animal Research Advisory Committee, National
Institutes of Health. Mice were used in experiments at 8–14
weeks of age.
Injection of vaccines into mice was performed by four
different methods: (1) intramuscular—vaccine suspension
was injected into the quadriceps muscles of the hind limbs;
(2) subcutaneous—virus suspension was injected under the
skin at the base of the tail; (3) scarification—virus
suspension (2 Al) was delivered either at the base of the
tail or at a shaven area of the skin in the lower part of the
vertebral column by fifteen pricks with a 25 G needle; (4)
intradermal—virus suspension was delivered with a jetinjector device, Biojector 2000 (Bioject Inc., Portland, OR),
using guidelines provided by the manufacturer, with slight
modifications. Prior to immunization with the Biojector
device, mice were anesthetized by intraperitoneal injection
of a solution of 1 Avertin dissolved in PBS [Avertin =
2,2,2-Tribromoethanol dissolved in tertiary amyl alcohol
(Aldrich Chemical Co., Milwaukee, WI)]. Each mouse
received 20 Al of avertin, per gram body weight. Mice were
shaved on both sides in the lower part of the vertebral
column around the tail region to reveal a clean skin. Virus
suspension loaded into a number 2 Biojector syringe was
injected into the shaven area, by placing a spacer affixed to
the mouth of the syringe perpendicular to the skin surface
and pressing the actuator. Injection of the virus suspension
is powered from a compressed CO2 cartridge.
Virus challenge
Vaccinia WR, purified by centrifugation through a
sucrose cushion, was used as the challenge strain through
the intranasal route. The LD50 of the virus stock was
determined using the method of Muench and Reed
(Lennette, 1964). In subsequent challenge experiments,
mice were weighed and anesthetized by intraperitoneal
injection of 20 Al Avertin per gram body weight. Each
mouse received 10 Al of virus suspension in the nares of
each nostril for a challenge dose total of 2  106 pfu (10
LD50) or 5  106 pfu (25 LD50). Mice were weighed daily
thereafter, and monitored for symptoms of vaccinia infec-
tion and death, for 3 weeks. Any mouse that lost 25% of
body weight at any time point after challenge was sacrificed.
Inactivated vaccinia virus ELISA
The detection and quantification of total vaccinia virus-
specific IgG and IgG isotypes (IgG1, IgG2a, IgG2b, and
IgG3) in serum samples were performed using Trioxsalen/
UV-inactivated vaccinia virus as antigen, as previously
described (Hanson et al., 1978; Tscharke et al., 2002) with
slight modifications. Preliminary experiments using crude
extracts of virus-infected cells and mock-infected cells
established that vaccinia immune sera did not react to any
appreciable extent to uninfected extracts of cells which were
used to prepare virus stocks for immunization. For all
quantitative ELISAs used to measure vaccinia-specific IgG
and IgG isotypes, the antigen was inactivated Dryvax virus.
Briefly, virus was purified from a suspension of infected
HeLa cells, pelleted through a sucrose cushion, re-
suspended in phosphate-buffered saline (PBS), vortexed,
sonicated and diluted to 2–3  108 pfu/Al. Trioxsalen was
added to a final concentration of 1 Ag/ml, and the virus
suspension was left at room temperature for 10 min. The
Trioxsalen-treated virus suspension was transferred into
100-mm-diameter petri dishes (7–10 ml per dish), and
exposed to ultraviolet light for 15 min using a Stratalinker-
1800 (Stratagene Inc.). The titer of an aliquot of untreated
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the inactivated virus suspension. For antibody ELISA, 96-
well Immulon 1B plates (ThermoLab Systems Inc., Frank-
lin, MA) were coated with the inactivated virus suspension
at approximately 106 pfu-equivalent per well, in PBS. Plates
were stored at 4 -C overnight. Following removal of
unbound antigen, plates were blocked with PBS/10% FBS
for 2 h at 37 -C. Wells were washed with PBS containing
10% FBS, and 0.05% Tween-20 (PBST). Serum samples
were serially diluted in PBST, and plates were incubated
with the diluted samples for 2 h at 37 -C. Excess serum was
removed from wells, and wells were washed as above.
Horseradish peroxidase (HRP)-conjugated goat anti-mouse
IgG (Southern Biotechnology Associates Inc., Birmingham,
AL), diluted in PBST, was added to all wells. For isotyping,
HRP-conjugated goat anti-mouse IgG1, IgG2a, IgG2b, or
IgG3 was added to appropriate wells at this stage. Plates
were incubated for 1 h at 37 -C and excess conjugate
antibody was washed off. A chromogenic HRP substrate,
ABTS/H2O2 (Kirkegarrd and Perry Laboratories, Gaithers-
burg, MD), was added to all wells. Color development was
stopped by adding a solution of 1% SDS to all wells. The
absorbance at 405 nm wavelength (OD405) was read on a
Versamax microplate reader (Molecular Devices Corpora-
tion, Sunnyvale, CA). The endpoint titer was defined as the
highest dilution of serum that gave an absorbance at 405 nm
value that was greater than that of the matched dilution of
normal pre-bleed mouse serum and was also 0.050.
EEV ELISA (A33R)
A33R-specific antibody titers were detected by ELISA
using recombinant A33R antigen. Briefly, recombinant
A33R was prepared by expressing the full-length vaccinia
virus A33R gene, using an alphavirus replicon vector
system, in 108 BHK-21 cells (Smerdou and Liljestrom,
1999). The recombinant A33R was partially purified and
enriched from cell lysate by single-step affinity chromatog-
raphy. Construction of the Semliki Forest virus expression
vector encoding A33R and its expression and affinity
purification will be described elsewhere (manuscript in
preparation). Immulon 2HB plates (ThermoLab Systems)
were coated with varying dilutions of enriched A33R
antigen to determine the optimal concentration of antigen
for an A33R ELISA. Plates were prepared and ELISAs
performed as described above for the inactivated vaccinia
virus.
Vaccinia neutralization
The detection and quantitation of vaccinia virus
neutralizing antibodies in serum samples were performed
using a novel assay based on the expression of a reporter
gene encoding h-galactosidase (Manischewitz et al., 2003).
Briefly, a recombinant vaccinia virus expressing h-gal-
actosidase, vSC56 (Chakrabarti et al., 1997), was incu-bated with serial dilutions of serum prior to infection of
HeLa cells. After 16 h, cells were lysed and the h-
galactosidase activity was determined as described. Neu-
tralization titers are expressed as the log 10 mean 50%
inhibitory dilution.
In vitro stimulation of spleen cells
Spleen cells from immunized and naı¨ve mice were
isolated as previously described (Meseda et al., 2002). Cells
were cultured in RPMI 1640 medium (supplemented with
Glutamax-1, h-Mercaptoethanol, non-essential amino acids,
HEPES, and 10% FBS, and containing 0.05% gentamicin),
at 106/ml (1 ml per well) in 24-well tissue culture plates.
Plated spleen cells were either stimulated with Trioxsalen/
UV-inactivated Vacc-NYCBH, at 106 pfu-equivalent per
well, or with uninfected BS-C-1 cell lysate. Plates were
incubated at 37 -C under 5% CO2 and each well was
harvested after 72 h. Culture supernatants were cleared of
suspended cells by centrifugation at 2000 rpm for 5 min, at
4 -C. Supernatants were stored at 20 -C, and analyzed for
specific cytokines as described previously.
Statistical analysis
Significant differences between groups, defined as P <
0.05, were analyzed using an unpaired, two-tailed Student’s
t test, using InStat software (GraphPad Software, Inc.).Acknowledgments
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